Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans
20-Oct-2003 -
Following the recent announcement of its positive asthma allergen challenge study
following treatment with its selectin antagonist bimosiamose, Revotar Biopharmaceu-ticals
AG announced today the results of a clinical investigative study which were
first presented at the European Respiratory ...
asthma
chronic inflammation
clinical trials
+2